Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer (PRROC) - the GCIG Symptom Benefit Study

Roncolato, FT; Joly, F; O'Connell, R; Lanceley, A; Hilpert, F; Buizen, L; Okamoto, A; Roncolato, FT; Joly, F; O'Connell, R; Lanceley, A; Hilpert, F; Buizen, L; Okamoto, A; Aotani, E; Pignata, S; Donnellan, P; Oza, A; Avall-Lundqvist, E; Berek, JS; Heitz, F; Feeney, A; Berton-Rigaud, D; Stockler, MR; King, M; Friedlander, M; GCIG Symptom Benefit Group, ; - view fewer (2017) Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer (PRROC) - the GCIG Symptom Benefit Study. The Oncologist (In press).

http://ift.tt/2p418Ei